Gavi and World Bank sign MoU to mobilise $2 billion

Gavi and the World Bank Group signed a Memorandum of Understanding on December 6 2025 to mobilise at least US$2 billion in joint financing over 2026-2030 for immunisation, primary healthcare, and regional vaccine manufacturing. The collaboration sets new expectations for corporate and sovereign governance disclosure on health access and supply-chain resilience under the Social and Governance pillars of ESG.

Gavi, the Vaccine Alliance, and the World Bank Group signed a new Memorandum of Understanding on December 6 2025 to strengthen financing for immunisation and primary healthcare systems while supporting regional vaccine manufacturing, particularly across Africa. The partnership commits to mobilising at least US$2 billion in joint financing over 2026-2030, leveraging blended finance, buydowns, and guarantees alongside technical support in public financial management. The effort aligns with the African Union's goal of producing 60 percent of the continent's vaccine supply domestically by 2040 and the WBG's aim to deliver quality health services to 1.5 billion people by 2030.

The collaboration affects low- and lower-middle-income countries, the Gavi African Vaccine Manufacturing Accelerator, regional vaccine manufacturers, and health workforces. It supports countries transitioning from external support to sustainable financing under the Gavi Leap agenda, advancing country ownership and self-reliance. The AVMA will work with the WBG to build regulatory frameworks, strengthen local supply chains, and enhance workforce development. Strengthening primary care generates health-workforce employment and supports local supply chains. Since launching its health initiative 18 months ago, the World Bank Group has helped reach 375 million more people with quality, affordable services.

Global investors and emerging-market operators should monitor the mobilisation of the US$2 billion over 2026-2030 as a signal of commitment to closing health-equity gaps aligned with SDG 3. Stakeholders should track progress on regional vaccine manufacturing toward the African Union's 60-percent-by-2040 target, which enhances supply-chain resilience and national sovereignty. The collaboration demands new standards for corporate and sovereign governance disclosure regarding health access and security, translating public health investment into long-term economic stability and reduced geopolitical risk under the Social and Governance pillars of ESG.

Key figure — Joint financing commitment: at least US$2 billion over 2026-2030